Astaxanthin suppresses thrombosis by inhibiting both platelet activation and blood coagulation
British Journal of Pharmacology · 2026-06 · 183 (11) · 2890-2912
DOI: 10.1111/bph.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 17.02.2026. Verfasst von Lili Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic …. Hauptthemen laut MEDLINE: Thrombosis, Blood Coagulation, Platelet Activation, Fibrinolytic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Graduate Teaching and Research Project of Huazhong University of Science and Technology, Grant from Key Laboratory of Chinese Medicinal Resource and Chinese Herbal Compound of the Ministry of Education, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Purpose Thrombosis, the leading cause of death worldwide, involves both platelet activation and coagulation reaction. Astaxanthin (ASX) is a carotenoid with potent antioxidant activity and beneficial effects to the cardiovascular system. This study aims to systematically elucidate the antithrombotic potential of ASX and the underlying mechanisms. Experimental Approach Rats and mice were treated with ASX by gavage to examine the in vivo effects of ASX. Human platelets and liver cells were directly treated with ASX to evaluate its in vitro effects. Network pharmacology and immunoblotting were performed to analyse the targets of ASX. Thrombus components including platelets and fibrin were visualized by specific fluorescent antibodies using intravital microscopy. Key Results ASX treatment led to attenuated platelet aggregation, adhesion, spreading, clot retraction and reduced integrin activation and granule secretion. ASX inhibited reactive oxygen species (ROS) production, and its downstream signalling pathways PI3K/Akt/mTOR and MAPK/ERK during platelet activation. ASX suppressed blood coagulation, both extrinsic and intrinsic, by interfering with hepatic transcription of coagulation factors through reducing hepatic ROS and ROS‐responsive hepatocyte nuclear factor 4 α (HNF4 α ). Treatment with ASX in human platelets and liver cells recapitulated the observations in animals. ASX and aspirin comparably inhibited FeCl 3 ‐induced arterial thrombosis and stenosis‐induced venous thrombosis. However, unlike aspirin which targets only platelets, ASX inhibited both platelets and fibrin in the cremaster thrombosis model without causing excessive bleeding. Conclusion and Implications ASX exhibits multiple antithrombotic effects by suppressing platelet‐ and hepatic‐ROS and the downstream responsive pathways. ASX represents a novel strategy for thrombosis prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wu…
- Key Laboratory of Chinese Medicinal Resource and Chinese Herbal Compound of the Ministry of Education, Wuhan, China.
- Department of Pharmacology, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
- Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- The Engineering and Technology Research Center on Dermatological Medications, Yichang, China.
- Jingzhou Natural Astaxanthin Application Research Center, Jingzhou, China.
ORCID-Profile: Chao Fang
Förderung
- Graduate Teaching and Research Project of Huazhong University of Science and Technology
- Grant from Key Laboratory of Chinese Medicinal Resource and Chinese Herbal Compound of the Ministry of Education
- National Natural Science Foundation of China
- Natural Science Fund of Hubei Province
- Wuhan Dawn Program
- Global Research Award and the Supplement Award from the American Society of Hematology
- Guizhou Provincial Science and Technology Project
- Science and Technology Fund Project of Guizhou Provincial Health Commission
Zitieren
APA
Zhang, L., Luo, Y., Lei, N., Chen, S., Lv, K., Xiang, H., Tang, Z., Li, B., Zheng, X., Li, S., Wang, X., Li, M., Liu, H., Zhang, B., Wang, J., Xu, X., & Fang, C. (2026). Astaxanthin suppresses thrombosis by inhibiting both platelet activation and blood coagulation. British Journal of Pharmacology, 183(11), 2890-2912. https://doi.org/10.1111/bph.70363
Vancouver
Zhang L, Luo Y, Lei N, Chen S, Lv K, Xiang H, et al. Astaxanthin suppresses thrombosis by inhibiting both platelet activation and blood coagulation. British Journal of Pharmacology. 2026;183(11):2890-2912. doi:10.1111/bph.70363
BibTeX
@article{Zhang2026,
author = {Zhang, Lili and Luo, Yadan and Lei, Ningwan and Chen, Shuai and Lv, Keyu and Xiang, Huiqin and Tang, Zhaoming and Li, Bicheng and Zheng, Xinyue and Li, Shimei and Wang, Xue and Li, Mingfeng and Liu, Hongtao and Zhang, Banghua and Wang, Jinyu and Xu, Xulin and Fang, Chao},
title = {Astaxanthin suppresses thrombosis by inhibiting both platelet activation and blood coagulation},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {11},
pages = {2890--2912},
doi = {10.1111/bph.70363}
}
EUVIMED